Strategic Expansion AGI recently launched AGI Ventures, a venture-development division aimed at emerging biotechnology companies, signaling openness to strategic partnerships, investment opportunities, and early-access collaborations that could extend AGI’s preclinical capabilities to portfolio startups.

Primate Research Leader Position AGI as the largest nonhuman primate research center in the United States with extensive colony management and on-site animal resources to attract sponsors requiring advanced nonclinical primate models, long-term studies, and regulated development support.

Full-spectrum Capabilities Highlight AGI’s end-to-end preclinical services from rodent studies to IND-enabling GLP work, including PK/PD, toxicology, imaging, bioanalysis, tissue collection, and quarantine, enabling one-stop outsourcing for pharma, biotech, government, and academia.

Quality and Compliance Focus Despite recent welfare-law concerns, emphasize independent quality oversight and comprehensive, regulated pathways from proof of concept to development, while proactively addressing animal welfare and operational compliance to restore trust and broaden client prospects.

Diverse Market Access Leverage AGI’s government and NIH-related history, large grant recognition, and government contracts to pursue opportunities with agencies and institutions seeking CRO partners for infectious disease, neuroscience, vaccines, gene therapy, and biologics programs.